Ocular surface disease in patients under topical treatment for glaucoma
Post author correction
Article Type: ORIGINAL RESEARCH ARTICLE
Article Subject: Glaucoma
AuthorsFrancisco Pérez-Bartolomé, Jose M. Martínez-de-la-Casa, Pedro Arriola-Villalobos, Cristina Fernández-Pérez, Vicente Polo, Julián García-Feijoó
To examine the relationship between ocular surface disease (OSD) and topical antiglaucoma therapy.
A total of 211 eyes of 211 patients with open-angle glaucoma or ocular hypertension on topical medication were recruited over 10 months. Controls were 51 eyes of 51 healthy age- and sex-matched volunteers. In each patient, we recorded the intraocular pressure-lowering eyedrops used, the number of medications used, and daily and cumulative preservative concentrations (PC). Main outcome measures were fluorescein corneal staining score (Oxford scale), lower tear meniscus height (LTMH) (spectral-domain optical coherence tomography), noninvasive tear film breakup time (NI-TBUT) (Oculus Keratograph 5M), and OSD symptom questionnaire index (OSDI).
Compared to controls, significantly higher OSDI (median [interquartile range] 10.24 [4.54-18.94] vs 2.5 [0-12.5]; p<0.001) and corneal staining (≥1: 64.93% vs 32.61%; p<0.001) scores were recorded in the medication group. The NI-TBUT and LTMH failed to vary between the groups (p>0.05). A higher daily PC was associated with a lower LTMH (R −0.142; p = 0.043). In the medication group, multivariate analysis identified correlations between benzalkonium chloride (BAK) (odds ratio [OR] 1.56) and BAK plus polyquaternium-containing drops (OR 5.09) or higher OSDI (OR 1.06) and abnormal corneal staining test results and between older age (mean ratio [MR] 1.05), longer treatment duration (MR 1.02), or corneal staining presence (MR 1.22) and a higher OSDI score.
Ocular surface disease was more prevalent in the medication group. The main factors impacting OSD were drops with preservatives, longer treatment duration, and older age.
- • Accepted on 30/03/2017
- • Available online on 10/05/2017
This article is available as full text PDF.
- Pérez-Bartolomé, Francisco [PubMed] [Google Scholar] 1, 2, * Corresponding Author (firstname.lastname@example.org)
- Martínez-de-la-Casa, Jose M. [PubMed] [Google Scholar] 1, 2
- Arriola-Villalobos, Pedro [PubMed] [Google Scholar] 1, 2
- Fernández-Pérez, Cristina [PubMed] [Google Scholar] 3
- Polo, Vicente [PubMed] [Google Scholar] 4
- García-Feijoó, Julián [PubMed] [Google Scholar] 1, 2
Ophthalmology Department, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria San Carlos (IdISSC), Madrid - Spain
Ophthalmology Department, Ramon Castroviejo Institute, Complutense University of Madrid, Madrid - Spain
Department of Epidemiology and Preventive Medicine, Hospital Clínico San Carlos, Complutense University of Madrid, Madrid - Spain
Department of Ophthalmology, Hospital Miguel Servet, Zaragoza - Spain